December 1, 2021
Taiho Pharmaceutical said on November 30 that it has acquired exclusive development and marketing rights in Japan and certain other territories in Asia (excluding China) for two anti-TIGIT antibodies under development by US-based Arcus Biosciences. The companies signed an option...read more